Summary:
The Purpose of this study is to access the safty and immune response or mRNA-1345 and mRNA vaccine targeting RSV when given alone or coadministered with SARS-CoV-2 vaccine in health older adults.
Study details include:
- The Study duration will be up for 7 months
- The treatment is 2 injections
- The visit frequency will be 3 visits inthe frist month.
Criteria:To be Qualified in RSV & Covid study please see the requirments.
- Age 50 and older
- Fully Vaccinated for COVID-19 with an approved primary seies accprding to yhr locally authorized or approved regimen.If te most recent COVID-19 vaccine was part of a primary series, it must be 150 days before Day 1 .If the most recent COVID-19 vaccine was a booster dose, it must be 120 days before day 1.
- If you are a Female participants have to be on contraception for 3 months while being on the study.
- Able to comply with study requirments, including access to transportation for study visits
Qualified Participants May Receive:
Payment for this is study is $ 1,230